論文・総説 - 永田　哲也

分割表示 >> ／  全件表示  109 件中 1 - 109 件目

  1. Matsubayashi T, Yoshioka K, Lei Mon SS, Katsuyama M, Jia C, Yamaguchi T, Hara RI, Nagata T, Nakagawa O, Obika S, Yokota T. Favorable efficacy and reduced acute neurotoxicity by antisense oligonucleotides with 2',4'-BNA/LNA with 9-(aminoethoxy)phenoxazine. Molecular therapy. Nucleic acids. 2024.06; 35 (2): 102161. ( PubMed, DOI )

  2. Sano T, Nagata T, Ebihara S, Yoshida-Tanaka K, Nakamura A, Sasaki A, Shimozawa A, Mochizuki H, Uchihara T, Hasegawa M, Yokota T. Effects of local reduction of endogenous α-synuclein using antisense oligonucleotides on the fibril-induced propagation of pathology through the neural network in wild-type mice. Acta neuropathologica communications. 2024.05; 12 (1): 75. ( PubMed, DOI )

  3. Yum J, Aulia F, Kamiya K, Hori M, Qiao N, Kim BS, Naito M, Ogura S, Nagata T, Yokota T, Uchida S, Obika S, Kim HJ, Miyata K. Hydrophobicity Tuning of Cationic Polyaspartamide Derivatives for Enhanced Antisense Oligonucleotide Delivery. Bioconjugate chemistry. 2024.02; 35 (2): 125-131. ( PubMed, DOI )

  4. Watanabe N, Tone Y, Nagata T, Masuda S, Saito T, Motohashi N, Takagaki K, Aoki Y, Takeda S. Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide. Molecular therapy. Nucleic acids. 2023.12; 34 102034. ( PubMed, DOI )

  5. Yanagidaira M, Yoshioka K, Nagata T, Nakao S, Miyata K, Yokota T. Effects of combinations of gapmer antisense oligonucleotides on the target reduction. Molecular biology reports. 2023.04; 50 (4): 3539-3546. ( PubMed, DOI )

  6. Li F, Ichinose K, Ishibashi S, Yamamoto S, Iwasawa E, Suzuki M, Yoshida-Tanaka K, Yoshioka K, Nagata T, Hirabayashi H, Mogushi K, Yokota T. Preferential delivery of lipid-ligand conjugated DNA/RNA heteroduplex oligonucleotide to ischemic brain in hyperacute stage. Molecular therapy : the journal of the American Society of Gene Therapy. 2023.04; 31 (4): 1106-1122. ( PubMed, DOI )

  7. Jia C, Lei Mon SS, Yang Y, Katsuyama M, Yoshida-Tanaka K, Nagata T, Yoshioka K, Yokota T. Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route. Molecular therapy. Nucleic acids. 2023.03; 31 182-196. ( PubMed, DOI )

  8. Amano A, Sanjo N, Araki W, Anraku Y, Nakakido M, Matsubara E, Tomiyama T, Nagata T, Tsumoto K, Kataoka K, Yokota T. Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brain. Journal of nanobiotechnology. 2023.01; 21 (1): 36. ( PubMed, DOI )

  9. Goto A, Yamamoto S, Igari T, Matsumoto SI, Chisaki I, Iida K, Nakayama M, Oda A, Kakoi Y, Uchida A, Miyata K, Nishikawa M, Nagata T, Kusuhara H, Yokota T, Hirabayashi H. Quantitative Model Analysis and Simulation of Pharmacokinetics and Metastasis-Associated Lung Adenocarcinoma 1 RNA Knockdown Effect After Systemic Administration of Cholesterol-Conjugated DNA/RNA Heteroduplex Oligonucleotide Crossing Blood-Brain Barrier of Mice. The Journal of pharmacology and experimental therapeutics. 2023.01; 384 (1): 197-204. ( PubMed, DOI )

  10. Nishi R, Ohyagi M, Nagata T, Mabuchi Y, Yokota T. Regulation of activated microglia and macrophages by systemically administered DNA/RNA heteroduplex oligonucleotides. Molecular therapy : the journal of the American Society of Gene Therapy. 2022.06; 30 (6): 2210-2223. ( PubMed, DOI )

  11. Miyashita A, Kobayashi M, Ishibashi S, Nagata T, Chandrasekhar A, Zochodne DW, Yokota T. The Role of Long Noncoding RNA MALAT1 in Diabetic Polyneuropathy and the Impact of Its Silencing in the Dorsal Root Ganglion by a DNA/RNA Heteroduplex Oligonucleotide. Diabetes. 2022.06; 71 (6): 1299-1312. ( PubMed, DOI )

  12. Kaburagi H, Nagata T, Enomoto M, Hirai T, Ohyagi M, Ihara K, Yoshida-Tanaka K, Ebihara S, Asada K, Yokoyama H, Okawa A, Yokota T. Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve. Molecular therapy. Nucleic acids. 2022.06; 28 910-919. ( PubMed, DOI )

  13. Nagata T, Dwyer CA, Yoshida-Tanaka K, Ihara K, Ohyagi M, Kaburagi H, Miyata H, Ebihara S, Yoshioka K, Ishii T, Miyata K, Miyata K, Powers B, Igari T, Yamamoto S, Arimura N, Hirabayashi H, Uchihara T, Hara RI, Wada T, Bennett CF, Seth PP, Rigo F, Yokota T. Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. Nature biotechnology. 2021.12; 39 (12): 1529-1536. ( PubMed, DOI )

  14. Ohyagi M, Nagata T, Ihara K, Yoshida-Tanaka K, Nishi R, Miyata H, Abe A, Mabuchi Y, Akazawa C, Yokota T. DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo. Nature communications. 2021.12; 12 (1): 7344. ( PubMed, DOI )

  15. Motohiro Suzuki, Satoru Ishibashi, Eri Iwasawa , Takahiro Oguma, Yasuhiro Saito, Fuying Li, Shinichi Otsu, Keiko Ichinose, Kotaro Yoshioka, Tetsuya Nagata, Takanori Yokota. Effective silencing of miR-126 after ischemic stroke by means of intravenous α-tocopherol-conjugated heteroduplex oligonucleotide in mice. Scientific reports. 2021.07; 11 (1): 14237. ( PubMed, DOI )

  16. Asada K, Sakaue F, Nagata T, Zhang JC, Yoshida-Tanaka K, Abe A, Nawa M, Nishina K, Yokota T. Short DNA/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing. Nucleic acids research. 2021.05; 49 (9): 4864-4876. ( PubMed, DOI )

  17. Ono D, Asada K, Yui D, Sakaue F, Yoshioka K, Nagata T, Yokota T. Separation-related rapid nuclear transport of DNA/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking. Molecular therapy. Nucleic acids. 2021.03; 23 1360-1370. ( PubMed, DOI )

  18. Yutaro Asami, Tetsuya Nagata, Kotaro Yoshioka, Taiki Kunieda, Kie Yoshida-Tanaka, C Frank Bennett, Punit P Seth, Takanori Yokota. Efficient Gene Suppression by DNA/DNA Double-Stranded Oligonucleotide In Vivo. Molecular therapy : the journal of the American Society of Gene Therapy. 2021.02; 29 (2): 838-847. ( PubMed, DOI )

  19. Yuki Kishimoto, Osamu Nakagawa, Akane Fujii, Kotaro Yoshioka, Tetsuya Nagata, Takanori Yokota, Yoshiyuki Hari, Satoshi Obika. 2',4'-BNA/LNA with 9-(2-Aminoethoxy)-1,3-diaza-2-oxophenoxazine Efficiently Forms Duplexes and Has Enhanced Enzymatic Resistance*. Chemistry (Weinheim an der Bergstrasse, Germany). 2021.02; 27 (7): 2427-2438. ( PubMed, DOI )

  20. Naito M, Chaya H, Toh K, Kim BS, Hayashi K, Fukushima S, Nagata T, Yokota T, Kataoka K, Miyata K. Structural tuning of oligonucleotides for enhanced blood circulation properties of unit polyion complexes prepared from two-branched poly(ethylene glycol)-block-poly(l-lysine). Journal of controlled release : official journal of the Controlled Release Society. 2021.02; 330 812-820. ( PubMed, DOI )

  21. Nagata Tetsuya. BBB透過性ヘテロ二重鎖オリゴヌクレオチド(BBB-penetrating heteroduplex oligonucleotide) 臨床神経学. 2020.11; 60 (Suppl.): S255. ( 医中誌 )

  22. Ohyagi Masaki, Nagata Tetsuya, Ihara Kensuke, Nishi Rieko, Mabuchi Yo, Akazawa Chihiro, Yokota Takanori. DNA/RNAヘテロ二重鎖オリゴヌクレオチド技術を用いた多発性硬化症に対する新規治療戦略(New therapeutic strategy for multiple sclerosis by DNA/RNA heteroduplex oligonucleotide technology) 臨床神経学. 2020.11; 60 (Suppl.): S293. ( 医中誌 )

  23. Jia Chunyan, Yoshioka Kotaro, Mon Su Su Lei, Tanaka Kie, Nagata Tetsuya, Yokota Takanori. CNS疾患に対するヘテロ二重鎖オリゴヌクレオチド使用による治療指標の改善(Hetereoduplex oligonucleotides technology improves therapeutic index for CNS diseases) 臨床神経学. 2020.11; 60 (Suppl.): S323. ( 医中誌 )

  24. Yokota Takanori, Nagata Tetsuya, Dwyer Chrissa, Yoshida Kie, Yoshioka Kotaro, Seth Punit, Rigo Frank, Bennett Frank. BBB透過性ヘテロ二重鎖オリゴヌクレオチド(HDO)の開発(Development of BBB-penetrating heteroduplex oligonucleotides(HDO)) 臨床神経学. 2020.11; 60 (Suppl.): S314. ( 医中誌 )

  25. Mishra V, Re DB, Le Verche V, Alvarez MJ, Vasciaveo A, Jacquier A, Doulias PT, Greco TM, Nizzardo M, Papadimitriou D, Nagata T, Rinchetti P, Perez-Torres EJ, Politi KA, Ikiz B, Clare K, Than ME, Corti S, Ischiropoulos H, Lotti F, Califano A, Przedborski S. Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow. Nature communications. 2020.11; 11 (1): 5579. ( PubMed, DOI )

  26. Kim BS, Naito M, Chaya H, Hori M, Hayashi K, Min HS, Yi Y, Kim HJ, Nagata T, Anraku Y, Kishimura A, Kataoka K, Miyata K. Noncovalent Stabilization of Vesicular Polyion Complexes with Chemically Modified/Single-Stranded Oligonucleotides and PEG-b-guanidinylated Polypeptides for Intracavity Encapsulation of Effector Enzymes Aimed at Cooperative Gene Knockdown. Biomacromolecules. 2020.10; 21 (10): 4365-4376. ( PubMed, DOI )

  27. Teramoto N, Sugihara H, Yamanouchi K, Nakamura K, Kimura K, Okano T, Shiga T, Shirakawa T, Matsuo M, Nagata T, Daimon M, Matsuwaki T, Nishihara M. Pathological evaluation of rats carrying in-frame mutations in the dystrophin gene: a new model of Becker muscular dystrophy. Disease models & mechanisms. 2020.09; 13 (9): ( PubMed, DOI )

  28. Hara Y, Mizobe Y, Inoue YU, Hashimoto Y, Motohashi N, Masaki Y, Seio K, Takeda S, Nagata T, Wood MJA, Inoue T, Aoki Y. Novel EGFP reporter cell and mouse models for sensitive imaging and quantification of exon skipping. Scientific reports. 2020.06; 10 (1): 10110. ( PubMed, DOI )

  29. Lei Mon SS, Yoshioka K, Jia C, Kunieda T, Asami Y, Yoshida-Tanaka K, Piao W, Kuwahara H, Nishina K, Nagata T, Yokota T. Highly efficient gene silencing in mouse brain by overhanging-duplex oligonucleotides via intraventricular route. FEBS letters. 2020.05; 594 (9): 1413-1423. ( PubMed, DOI )

  30. Yokoyama H, Hirai T, Nagata T, Enomoto M, Kaburagi H, Leiyo L, Motoyoshi T, Yoshii T, Okawa A, Yokota T. DNA Microarray Analysis of Differential Gene Expression in the Dorsal Root Ganglia of Four Different Neuropathic Pain Mouse Models. Journal of pain research. 2020; 13 3031-3043. ( PubMed, DOI )

  31. Yoshioka Kotaro, Su Su Lei Mon , Jia Chunyan, Yamada Hiroki, Asami Yutaro, Tanaka Kie, Wenying Piao, Kuwahara Hiroya, Nishina Kazutaka, Nagata Tetsuya, Yokota Takanori. CNSを標的としたオーバーハングヘテロ二2本鎖核酸を用いた新しいアンチセンスオリゴヌクレオチド治療(A novel antisense oligonucleotide therapy by overhanging heteroduplex oligonucleotide targeting CNS) 臨床神経学. 2019.11; 59 (Suppl.): S408. ( 医中誌 )

  32. Yoshioka K, Kunieda T, Asami Y, Guo H, Miyata H, Yoshida-Tanaka K, Sujino Y, Piao W, Kuwahara H, Nishina K, Hara RI, Nagata T, Wada T, Obika S, Yokota T. Highly efficient silencing of microRNA by heteroduplex oligonucleotides. Nucleic acids research. 2019.08; 47 (14): 7321-7332. ( PubMed, DOI )

  33. Uehara T, Choong CJ, Nakamori M, Hayakawa H, Nishiyama K, Kasahara Y, Baba K, Nagata T, Yokota T, Tsuda H, Obika S, Mochizuki H. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease. Scientific reports. 2019.05; 9 (1): 7567. ( PubMed, DOI )

  34. Yoshiaki Masaki, Keishi Yamamoto, Takeshi Inde, Keita Yoshida, Atsuya Maruyama, Tetsuya Nagata, Jun Tanihata, Shin'ichi Takeda, Mitsuo Sekine, Kohji Seio. Synthesis of 2'-O-(N-methylcarbamoylethyl) 5-methyl-2-thiouridine and its application to splice-switching oligonucleotides. Bioorg. Med. Chem. Lett.. 2018.12; 29 (2): 160-163. ( PubMed, DOI )

  35. Nagata Tetsuya. DNA/RNAヘテロ2本鎖核酸の最近の進歩(Recent progress of DNA/RNA heteroduplex oligonucleotide) 臨床神経学. 2018.12; 58 (Suppl.): S47. ( 医中誌 )

  36. Kenji Rowel Q Lim*, Yusuke Echigoya*, Tetsuya Nagata*, Mutsuki Kuraoka, Masanori Kobayashi, Yoshitsugu Aoki, Terence Partridge, Rika Maruyama, Shin'ichi Takeda, Toshifumi Yokota *Equal Contribution . Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates. Mol. Ther.. 2018.10; ( PubMed, DOI )

  37. Naoki Watanabe*, Tetsuya Nagata*, Youhei Satou, Satoru Masuda, Takashi Saito, Hidetoshi Kitagawa, Hirofumi Komaki, Kazuchika Takagaki, Shin'ichi Takeda *Equal Contribution. NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids. 2018.09; 13 442-449. ( PubMed, DOI )

  38. Hara Y, Mizobe Y, Miyatake S, Takizawa H, Nagata T, Yokota T, Takeda S, Aoki Y. Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy. Methods in molecular biology (Clifton, N.J.). 2018; 1828 553-564. ( PubMed, DOI )

  39. Uehara T., Choong C. J., Hayakawa H., Kasahara Y., Nagata T., Yokota T., Baba K., Nakamori M., Obika S., Mochizuki H.. Antisense oligonucleotides containing amido-bridged nucleic acid reduce SNCA expression and improve motor function in Parkinson's disease animal models JOURNAL OF THE NEUROLOGICAL SCIENCES. 2017.10; 381 1044-1045. ( DOI )

  40. Yoshioka K., Kunieda T., Asami Y., Sujino Y., Tanaka K., Piao W., Kuwahara H., Nishina K., Nagata T., Yokota T.. Dual overhanging-duplex oligonucleotide improved efficacy and safety in gene therapy for FAP JOURNAL OF THE NEUROLOGICAL SCIENCES. 2017.10; 381 140. ( DOI )

  41. Hitoshi Suzuki, Yoshitsugu Aoki, Toshiki Kameyama, Takashi Saito, Satoru Masuda, Jun Tanihata, Tetsuya Nagata, Akila Mayeda, Shin'ichi Takeda, Toshifumi Tsukahara. Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot. Int J Mol Sci. 2016.10; 17 (10): ( PubMed, DOI )

  42. Mutsuki Kuraoka, En Kimura, Tetsuya Nagata, Takashi Okada, Yoshitsugu Aoki, Hisateru Tachimori, Naohiro Yonemoto, Michihiro Imamura, Shin'ichi Takeda. Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy. Am. J. Pathol.. 2016.05; 186 (5): 1302-1312. ( PubMed, DOI )

  43. Koichi Kimura, Hiroyuki Morita, Masao Daimon, Masaru Horio, Takayuki Kawata, Tomoko Nakao, Megumi Hirokawa, Ruriko Kitao, Daisuke Watanabe, Tetsuo Komori, Tetsuya Nagata, Shin'ichi Takeda, Hirofumi Komaki, Kazuhiko Segawa, Takashi Nakajima, Katsu Takenaka, Issei Komuro. Utility of Cystatin C for Estimating Glomerular Filtration Rate in Patients With Muscular Dystrophy. Int Heart J. 2016.05; 57 (3): 386-388. ( PubMed, DOI )

  44. Masaki Y, Inde T, Nagata T, Tanihata J, Kanamori T, Seio K, Takeda S, Sekine M. Enhancement of exon skipping in mdx52 mice by 2'-O-methyl-2-thioribothymidine incorporation into phosphorothioate oligonucleotides Med Chem Commun. 2015.04; 6 630-633. ( DOI )

  45. 永田 哲也. 核酸医薬品の臨床開発状況 日本核酸医薬学会誌. 2023.07; 27 (1): 44-55. ( 医中誌 )

  46. 永田 哲也. 【核酸医薬の最近の進歩】神経疾患に対する核酸医薬　日本初の核酸医薬ビルトラルセン 脳神経内科. 2023.06; 98 (6): 851-857. ( 医中誌 )

  47. 永田 哲也. 【核酸医薬と神経疾患】核酸医療の基礎知識　DNA/RNAヘテロ2本鎖核酸 Clinical Neuroscience. 2023.05; 41 (5): 625-629. ( 医中誌 )

  48. 永田 哲也, 横田 隆徳. 【DDSで拓く創薬モダリティイノベーション】リガンド結合による核酸医薬の標的指向化 Drug Delivery System. 2023.01; 38 (1): 8-14. ( 医中誌 )

  49. 永田 哲也. 【核酸医薬の現状と今後の展望】DNA/RNAヘテロ核酸 BIO Clinica. 2021.12; 36 (14): 1361-1365. ( 医中誌 )

  50. 永田 哲也, 渡辺 直樹, 武田 伸一. 国内初のデュシェンヌ型筋ジストロフィーに対する核酸医薬品の開発 日本核酸医薬学会誌. 2021.06; 25 (1): 5-15. ( 医中誌 )

  51. 天野 晶子, 三條 伸夫, 中木戸 誠, 津本 浩平, 松原 悦朗, 永田 哲也, 西田 陽一郎, 横田 隆徳. ADモデルマウスにおける抗アミロイドβオリゴマー抗体陽性像の経時変化 Dementia Japan. 2020.10; 34 (4): 519. ( 医中誌 )

  52. 横山 裕之, 平井 高志, 榎本 光裕, 鏑木 秀俊, 吉井 俊貴, 永田 哲也, 横田 隆徳, 大川 淳. DNAマイクロアレイを用いたマウス腰部後根神経節における神経障害性疼痛関連遺伝子の調査 日本整形外科学会雑誌. 2020.09; 94 (8): S1844. ( 医中誌 )

  53. 西 李依子, 永田 哲也, 横田 隆徳. 【RNAサイレンシングと疾患】RNAサイレンシングと神経疾患 Medical Science Digest. 2020.08; 46 (9): 555-558. ( 医中誌 )

  54. 柳平 貢, 永田 哲也, 横田 隆徳. 【よくわかる遺伝子治療-実用化の現状と展望】遺伝子治療総論　DNA/RNAヘテロ核酸による遺伝子発現抑制 Clinical Neuroscience. 2020.03; 38 (3): 319-322. ( 医中誌 )

  55. 三浦 元輝, 永田 哲也, 横田 隆徳. 【ALS(筋萎縮性側索硬化症)治療の最前線】ALS治療の新たなモダリティとしての核酸医薬 医学のあゆみ. 2020.02; 272 (6): 511-516. ( 医中誌 )

  56. 大谷木 正貴, 永田 哲也, 井原 健介, 吉田 規恵, 西 李依子, 馬渕 洋, 赤澤 智宏, 横田 隆徳. DNA/RNAヘテロ2本鎖核酸によるリンパ球制御を介した神経免疫疾患の新規治療法の開発 神経免疫学. 2019.09; 24 (1): 93. ( 医中誌 )

  57. 永田 哲也. 【神経疾患の現在とこれから】診療の最前線　脊髄性筋萎縮症と核酸医薬 内科. 2019.06; 123 (6): 1279-1283. ( 医中誌 )

  58. 永田 哲也. アンチセンス・オリゴヌクレオチドの全身への投与によるDuchenne型筋ジストロフィーの患者のエキソン・スキップによる治療 臨床免疫・アレルギー科. 2019.01; 71 (1): 64-70. ( 医中誌 )

  59. 大原 正裕, 永田 哲也, 横田 隆徳. 【核酸医薬研究の進歩】核酸医薬総論とヘテロ2本鎖核酸 神経内科. 2018.11; 89 (5): 510-517. ( 医中誌 )

  60. 永田 哲也. 【核酸医薬による認知症・神経変性疾患の治療法開発】核酸医薬品の開発の現状 Dementia Japan. 2018.10; 32 (4): 589-596. ( 医中誌 )

  61. 横山 裕之, 平井 高志, 榎本 光裕, 永田 哲也, 横田 隆徳, 大川 淳. DNAマイクロアレイを用いた神経障害性疼痛関連分子の調査 日本整形外科学会雑誌. 2018.08; 92 (8): S1800. ( 医中誌 )

  62. 山田 大貴, 永田 哲也, 横田 隆徳. 【神経難病と創薬】神経難病と核酸医薬による分子標的治療の現状 医薬ジャーナル. 2018.07; 54 (7): 1613-1621. ( 医中誌 )

  63. 馬嶋 貴正, 永田 哲也, 仁科 一隆, 横田 隆徳. 【核酸医薬の現状と展望】ヘテロ核酸の現状 最新医学. 2018.06; 73 (6): 781-786. ( 医中誌 )

  64. 永田 哲也. 【核酸医薬の現状と展望】核酸医薬と神経変性疾患 最新医学. 2018.06; 73 (6): 807-814. ( 医中誌 )

  65. 大谷木 正貴, 永田 哲也, 横田 隆徳. 【核酸医薬】DNA/RNAヘテロ2本鎖核酸(HDO)の開発 BIO Clinica. 2018.01; 33 (1): 6-10. ( 医中誌 )

  66. 東 美和, 永田 哲也, 横田 隆徳. 【脊髄小脳変性症(SCD)-最新診療マニュアル】これからの治療への展望　核酸医薬 Clinical Neuroscience. 2017.09; 35 (9): 1124-1127. ( 医中誌 )

  67. Tanihata J, Nagata T, Ito N, Saito T, Nakamura A, Minamisawa S, Aoki Y, Ruegg UT, Takeda S. Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition. Biochemical and biophysical research communications. 2018.09; ( PubMed, DOI )

  68. Zeniya S, Kuwahara H, Daizo K, Watari A, Kondoh M, Yoshida-Tanaka K, Kaburagi H, Asada K, Nagata T, Nagahama M, Yagi K, Yokota T. Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. Journal of controlled release : official journal of the Controlled Release Society. 2018.05; 283 126-134. ( PubMed, DOI )

  69. Komaki H*, Nagata T*, Saito T*, Masuda S, Takeshita E, Sasaki M, Tachimori H, Nakamura H, Aoki Y, Takeda S *Equal Contribution. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Science translational medicine. 2018.04; 10 (437): ( PubMed, DOI )

  70. Kuwahara H, Song J, Shimoura T, Yoshida-Tanaka K, Mizuno T, Mochizuki T, Zeniya S, Li F, Nishina K, Nagata T, Ito S, Kusuhara H, Yokota T. Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo. Scientific reports. 2018.03; 8 (1): 4377. ( PubMed, DOI )

  71. Kishimoto Y, Fujii A, Nakagawa O, Nagata T, Yokota T, Hari Y, Obika S. Synthesis and thermal stabilities of oligonucleotides containing 2'-O,4'-C-methylene bridged nucleic acid with a phenoxazine base. Organic & biomolecular chemistry. 2017.10; 15 (38): 8145-8152. ( PubMed, DOI )

  72. Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KRQ, Trieu N, Panesar D, Kuraoka M, Moulton HM, Saito T, Aoki Y, Iversen P, Sazani P, Kole R, Maruyama R, Partridge T, Takeda S, Yokota T. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America. 2017.04; 114 (16): 4213-4218. ( PubMed, DOI )

  73. Kimura K, Morita H, Daimon M, Kawata T, Nakao T, Lee SL, Hirokawa M, Ebihara A, Nakajima T, Ozawa T, Yonemochi Y, Aida I, Motoyoshi Y, Mikata T, Uchida I, Komori T, Kitao R, Nagata T, Takeda S, Komaki H, Segawa K, Takenaka K, Komuro I. Prognostic impact of venous thromboembolism in patients with Duchenne muscular dystrophy: Prospective multicenter 5-year cohort study. International journal of cardiology. 2015.07; 191 178-180. ( PubMed, DOI )

  74. Yoshioka K, Kuwahara H, Nishina K, Nagata T, Yokota T. [Recent progress and prospect in oligonucleotide therapeutics]. Nihon rinsho. Japanese journal of clinical medicine. 2015.06; 73 (6): 1057-1065. ( PubMed )

  75. Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K, Yokota T. Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids. 2015.02; 4 e225. ( PubMed, DOI )

  76. Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, Ikiz B, Hoffmann L, Koolen M, Nagata T, Papadimitriou D, Nagy P, Mitsumoto H, Kariya S, Wichterle H, Henderson CE, Przedborski S. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014.03; 81 (5): 1001-1008. ( PubMed, DOI )

  77. Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T, Takeda S. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Human molecular genetics. 2013.12; 22 (24): 4914-4928. ( PubMed, DOI )

  78. Kimura K, Takenaka K, Ebihara A, Uno K, Morita H, Nakajima T, Ozawa T, Aida I, Yonemochi Y, Higuchi S, Motoyoshi Y, Mikata T, Uchida I, Ishihara T, Komori T, Kitao R, Nagata T, Takeda S, Yatomi Y, Nagai R, Komuro I. Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy--prospective multicenter cohort study. International journal of cardiology. 2013.10; 168 (3): 1900-1904. ( PubMed, DOI )

  79. Echigoya Y, Lee J, Rodrigues M, Nagata T, Tanihata J, Nozohourmehrabad A, Panesar D, Miskew B, Aoki Y, Yokota T. Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice. PloS one. 2013; 8 (7): e69194. ( PubMed, DOI )

  80. Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic acid therapeutics. 2012.10; 22 (5): 306-315. ( PubMed, DOI )

  81. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proceedings of the National Academy of Sciences of the United States of America. 2012.08; 109 (34): 13763-13768. ( PubMed, DOI )

  82. Nagata T, Takeda S. Antisense oligos for muscular dystrophy. Rinsho shinkeigaku = Clinical neurology. 2010.11; 50 (11): 843. ( PubMed )

  83. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Molecular therapy : the journal of the American Society of Gene Therapy. 2010.11; 18 (11): 1995-2005. ( PubMed, DOI )

  84. Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson VL, Dawson TM, Chesselet MF, Przedborski S. Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free radical biology & medicine. 2009.10; 47 (7): 1049-1056. ( PubMed, DOI )

  85. Ohta Y, Kamiya T, Nagai M, Nagata T, Morimoto N, Miyazaki K, Murakami T, Kurata T, Takehisa Y, Ikeda Y, Asoh S, Ohta S, Abe K. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. Journal of neuroscience research. 2008.10; 86 (13): 3028-3037. ( PubMed, DOI )

  86. Nagata T, Ilieva H, Murakami T, Shiote M, Narai H, Ohta Y, Hayashi T, Shoji M, Abe K. Increased ER stress during motor neuron degeneration in a transgenic mouse model of amyotrophic lateral sclerosis. Neurological research. 2007.12; 29 (8): 767-771. ( PubMed, DOI )

  87. Nagata T, Nagano I, Shiote M, Narai H, Murakami T, Hayashi T, Shoji M, Abe K. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurological research. 2007.12; 29 (8): 772-776. ( PubMed, DOI )

  88. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature neuroscience. 2007.05; 10 (5): 615-622. ( PubMed, DOI )

  89. Hirano M, Yamamoto A, Mori T, Lan L, Iwamoto TA, Aoki M, Shimada K, Furiya Y, Kariya S, Asai H, Yasui A, Nishiwaki T, Imoto K, Kobayashi N, Kiriyama T, Nagata T, Konishi N, Itoyama Y, Ueno S. DNA single-strand break repair is impaired in aprataxin-related ataxia. Annals of neurology. 2007.02; 61 (2): 162-174. ( PubMed, DOI )

  90. Ohta Y, Nagai M, Nagata T, Murakami T, Nagano I, Narai H, Kurata T, Shiote M, Shoji M, Abe K. Intrathecal injection of epidermal growth factor and fibroblast growth factor 2 promotes proliferation of neural precursor cells in the spinal cords of mice with mutant human SOD1 gene. Journal of neuroscience research. 2006.10; 84 (5): 980-992. ( PubMed, DOI )

  91. Iwai M, Ikeda T, Hayashi T, Sato K, Nagata T, Nagano I, Shoji M, Ikenoue T, Abe K. Temporal profile of neural stem cell proliferation in the subventricular zone after ischemia/hypoxia in the neonatal rat brain. Neurological research. 2006.06; 28 (4): 461-468. ( PubMed, DOI )

  92. Suzuki N, Aoki M, Mizuno H, Onodera Y, Takahashi T, Nagata T, Tateyama M, Itoyama Y. Late-onset distal myopathy with rimmed vacuoles without mutation in the GNE or dysferlin genes. Muscle & nerve. 2005.12; 32 (6): 812-814. ( PubMed, DOI )

  93. Narai H, Nagano I, Ilieva H, Shiote M, Nagata T, Hayashi T, Shoji M, Abe K. Prevention of spinal motor neuron death by insulin-like growth factor-1 associating with the signal transduction systems in SODG93A transgenic mice. Journal of neuroscience research. 2005.11; 82 (4): 452-457. ( PubMed, DOI )

  94. Matsubara E, Nagata T, Kageyama Y, Shiote M, Namba R, Nagano I, Shoji M, Abe K. Unique cerebellar-cerebral form of autosomal recessive ataxia. The Tohoku journal of experimental medicine. 2005.09; 207 (1): 81-85. ( PubMed )

  95. Shiote M, Nagano I, Ilieva H, Murakami T, Narai H, Ohta Y, Nagata T, Shoji M, Abe K. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Neuroscience. 2005.01; 132 (1): 175-182. ( PubMed, DOI )

  96. Murakami T, Ilieva H, Shiote M, Nagata T, Nagano I, Shoji M, Abe K. Hypoxic induction of vascular endothelial growth factor is selectively impaired in mice carrying the mutant SOD1 gene. Brain research. 2003.11; 989 (2): 231-237. ( PubMed )

  97. Sakurai M, Nagata T, Abe K, Horinouchi T, Itoyama Y, Tabayashi K. Survival and death-promoting events after transient spinal cord ischemia in rabbits: induction of Akt and caspase3 in motor neurons. The Journal of thoracic and cardiovascular surgery. 2003.02; 125 (2): 370-377. ( PubMed, DOI )

  98. Sakurai M, Nagata T, Abe K, Horinouchi T, Itoyama Y, Tabayashi K. Oxidative damage and reduction of redox factor-1 expression after transient spinal cord ischemia in rabbits. Journal of vascular surgery. 2003.02; 37 (2): 446-452. ( PubMed, DOI )

  99. Nishino I, Noguchi S, Murayama K, Driss A, Sugie K, Oya Y, Nagata T, Chida K, Takahashi T, Takusa Y, Ohi T, Nishimiya J, Sunohara N, Ciafaloni E, Kawai M, Aoki M, Nonaka I. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology. 2002.12; 59 (11): 1689-1693. ( PubMed )

  100. Moreira MC, Barbot C, Tachi N, Kozuka N, Uchida E, Gibson T, Mendonça P, Costa M, Barros J, Yanagisawa T, Watanabe M, Ikeda Y, Aoki M, Nagata T, Coutinho P, Sequeiros J, Koenig M. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nature genetics. 2001.10; 29 (2): 189-193. ( PubMed, DOI )

  101. Nagata T, Aoki M, Hasegawa T, Shiga Y, Hayashi T, Higuchi J, Abe K, Tanno T, Konno H, Itoyama Y. [An autopsy case of atypical Friedreich's ataxia with chronic idiopathic intestinal pseudo-obstruction]. Rinsho shinkeigaku = Clinical neurology. 2001.07; 41 (7): 412-417. ( PubMed )

  102. Nagata T, Onodera H, Ohuchi M, Suzuki Y, Tago H, Fujihara K, Ishii N, Sugamura K, Shoji Y, Handa M, Tabayashi K, Itoyama Y. Decreased expression of c-myc family genes in thymuses from myasthenia gravis patients. Journal of neuroimmunology. 2001.04; 115 (1-2): 199-202. ( PubMed )

  103. Onodera J, Nagata T, Fujihara K, Ohuchi M, Ishii N, Sugamura K, Itoyama Y. Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus. Acta neurologica Scandinavica. 2000.10; 102 (4): 236-243. ( PubMed )

  104. Onodera Y, Aoki M, Tsuda T, Kato H, Nagata T, Kameya T, Abe K, Itoyama Y. High prevalence of spinocerebellar ataxia type 1 (SCA1) in an isolated region of Japan. Journal of the neurological sciences. 2000.09; 178 (2): 153-158. ( PubMed )

  105. Onodera H, Nakashima I, Fujihara K, Nagata T, Itoyama Y. Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis. The Tohoku journal of experimental medicine. 1999.12; 189 (4): 259-265. ( PubMed )

  106. Onodera H, Nagata T, Kanazawa M, Taguma Y, Itoyama Y. Increased plasma GDNF levels in patients with chronic renal diseases. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1999.06; 14 (6): 1604-1605. ( PubMed )

  107. Kikuchi A, Chida K, Misu T, Okita N, Takase S, Nagata T, Sakai K, Itoyama Y. [A case of limbic encephalitis associated with breast cancer developed in an HTLV-1 carrier]. Rinsho shinkeigaku = Clinical neurology. 1999.05; 39 (5): 555-559. ( PubMed )

  108. Aoki M, Abe K, Nagata T, Kameya T, Watanabe M, Onodera H, Mochizuki H, Itoyama Y. A Japanese family with Machado-Joseph disease characterized by initial emaciation and myoclonus. European journal of neurology : the official journal of the European Federation of Neurological Societies. 1995.11; 2 (5): 477-482. ( PubMed, DOI )

  109. Hayashi T, Onodera J, Nagata T, Mochizuki H, Itoyama Y. [A case of biopsy-proven sarcoid meningoencephalitis presented with hallucination, nominal aphasia and dementia]. Rinsho shinkeigaku = Clinical neurology. 1995.09; 35 (9): 1008-1011. ( PubMed )

< 前のページ - 次のページ >

  • 1
このページの先頭へ▲